[First scientific meeting of CRI (Rheumatism and Inflammation Club) under the patronage of FNSIM (French National Society of Internal Medicine) and FSR(French Society of Rheumatology) Paris, May 4, 2002].
Grateau
G
G
Service de médecine interne, hôpital Roger-Bisson, 4, rue Roger-Aini, 14100 Lisieux, France.
Geffray
L
L
Veyssier-Belot
C
C
D019268:Antibodies, Antineutrophil Cytoplasmic; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D005602:France; D013700:Giant Cell Arteritis / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D000069285:Infliximab; D007388:Internal Medicine; D009154:Mutation; D012219:Rheumatology; D012595:Scleroderma, Systemic / Q000188:drug therapy* / Q000209:etiology; D012955:Societies, Medical; D013577:Syndrome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000502:physiology; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000188:drug therapy* / Q000209:etiology
D019268:Antibodies, Antineutrophil Cytoplasmic; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab